FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883277239> ?p ?o ?g. }

• W2883277239 abstract "19-Nortestosterone C-17 epimers with prominent antiproliferative properties have been previously described. In our present study five novel 17α-19-nortestosterones (3–7) were synthesized to increase their beneficial biological activities with no associated undesired hormonal effects. The compounds were screened by a viability assay against a panel of human adherent gynecological cancer cell lines. Three of the tested derivatives (3, 4 and 5) exhibited a remarkable inhibitory effect on the proliferation of HeLa cells with IC50 values lower than that of our reference agent cisplatin (CIS). These three active agents also displayed considerable cancer selectivity as evidenced by their weaker growth inhibitory effect on non-cancerous fibroblast cells compared to CIS. The most potent newly synthesized 17α-chloro derivative (3) was selected for additional experiments in order to characterize its mechanism of action. Since nandrolone (19-nortestosterone, 1) is a structural analog with selective antiproliferative action on cervical carcinoma cells, it was utilized as a positive control in these studies. A lactate dehydrogenase (LDH) assay demonstrated a moderate cytotoxic effect of the test compounds. Cell cycle disturbance and the elevation of the hypodiploid population elicited by the test agents were detected by flow cytometry following propidium staining. The proapoptotic effects of the tested steroids were confirmed by fluorescent microscopy and a caspase-3 activity assay. Treatment-related caspase-9 activation without a substantial change in caspase-8 activity indicates the induction of the intrinsic apoptotic pathway. The selected agents directly influence the rate of tubulin assembly as evidenced by a polymerization assay. Yeast-based reporter gene assay revealed that the androgenic activity of the novel 19-nortestosterone derivative 3 is by multiple orders of magnitude weaker than that of the reference agent 1. Based on the behavior of the examined compounds it can be concluded that a halogen substitution of the 19-nortestosterone scaffold at the 17α position may produce compounds with unique biological activities. The results of the present study support that structurally modified steroids with negligible hormonal activity are a promising basis for the research and development of novel anticancer agents." @default.
• W2883277239 created "2018-08-03" @default.
• W2883277239 creator A5019659026 @default.
• W2883277239 creator A5021567722 @default.
• W2883277239 creator A5036837841 @default.
• W2883277239 creator A5048307237 @default.
• W2883277239 creator A5052576897 @default.
• W2883277239 creator A5053645710 @default.
• W2883277239 creator A5055987253 @default.
• W2883277239 creator A5065701986 @default.
• W2883277239 creator A5073784698 @default.
• W2883277239 date "2018-07-27" @default.
• W2883277239 modified "2023-10-17" @default.
• W2883277239 title "Antiproliferative Properties of Newly Synthesized 19-Nortestosterone Analogs Without Substantial Androgenic Activity" @default.
• W2883277239 cites W1533920571 @default.
• W2883277239 cites W157009165 @default.
• W2883277239 cites W1573844626 @default.
• W2883277239 cites W1616592835 @default.
• W2883277239 cites W1814628459 @default.
• W2883277239 cites W1820568833 @default.
• W2883277239 cites W1983964043 @default.
• W2883277239 cites W1985908765 @default.
• W2883277239 cites W1987623378 @default.
• W2883277239 cites W1999057673 @default.
• W2883277239 cites W2003778789 @default.
• W2883277239 cites W2004631970 @default.
• W2883277239 cites W2008667748 @default.
• W2883277239 cites W2008928107 @default.
• W2883277239 cites W2015245896 @default.
• W2883277239 cites W2022526347 @default.
• W2883277239 cites W2031375424 @default.
• W2883277239 cites W2033559611 @default.
• W2883277239 cites W2034933844 @default.
• W2883277239 cites W2036302072 @default.
• W2883277239 cites W2040551046 @default.
• W2883277239 cites W2064746517 @default.
• W2883277239 cites W2068450443 @default.
• W2883277239 cites W2070358111 @default.
• W2883277239 cites W2079798078 @default.
• W2883277239 cites W2088864187 @default.
• W2883277239 cites W2093455808 @default.
• W2883277239 cites W2102073771 @default.
• W2883277239 cites W2106060738 @default.
• W2883277239 cites W2114918609 @default.
• W2883277239 cites W2132960194 @default.
• W2883277239 cites W2137608289 @default.
• W2883277239 cites W2142777290 @default.
• W2883277239 cites W2155538506 @default.
• W2883277239 cites W2167166971 @default.
• W2883277239 cites W2172161665 @default.
• W2883277239 cites W2179224925 @default.
• W2883277239 cites W2187963245 @default.
• W2883277239 cites W2194484185 @default.
• W2883277239 cites W2220689555 @default.
• W2883277239 cites W233628489 @default.
• W2883277239 cites W2469631333 @default.
• W2883277239 cites W2486721152 @default.
• W2883277239 cites W2560322684 @default.
• W2883277239 cites W262406365 @default.
• W2883277239 cites W2722231853 @default.
• W2883277239 doi "https://doi.org/10.3389/fphar.2018.00825" @default.
• W2883277239 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6072853" @default.
• W2883277239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30100876" @default.
• W2883277239 hasPublicationYear "2018" @default.
• W2883277239 type Work @default.
• W2883277239 sameAs 2883277239 @default.
• W2883277239 citedByCount "8" @default.
• W2883277239 countsByYear W28832772392019 @default.
• W2883277239 countsByYear W28832772392020 @default.
• W2883277239 countsByYear W28832772392021 @default.
• W2883277239 countsByYear W28832772392022 @default.
• W2883277239 crossrefType "journal-article" @default.
• W2883277239 hasAuthorship W2883277239A5019659026 @default.
• W2883277239 hasAuthorship W2883277239A5021567722 @default.
• W2883277239 hasAuthorship W2883277239A5036837841 @default.
• W2883277239 hasAuthorship W2883277239A5048307237 @default.
• W2883277239 hasAuthorship W2883277239A5052576897 @default.
• W2883277239 hasAuthorship W2883277239A5053645710 @default.
• W2883277239 hasAuthorship W2883277239A5055987253 @default.
• W2883277239 hasAuthorship W2883277239A5065701986 @default.
• W2883277239 hasAuthorship W2883277239A5073784698 @default.
• W2883277239 hasBestOaLocation W28832772391 @default.
• W2883277239 hasConcept C1491633281 @default.
• W2883277239 hasConcept C153911025 @default.
• W2883277239 hasConcept C181199279 @default.
• W2883277239 hasConcept C185592680 @default.
• W2883277239 hasConcept C190283241 @default.
• W2883277239 hasConcept C202751555 @default.
• W2883277239 hasConcept C2775934118 @default.
• W2883277239 hasConcept C2777318727 @default.
• W2883277239 hasConcept C2777366897 @default.
• W2883277239 hasConcept C2777752497 @default.
• W2883277239 hasConcept C2908647359 @default.
• W2883277239 hasConcept C31573885 @default.
• W2883277239 hasConcept C53227056 @default.
• W2883277239 hasConcept C553184892 @default.
• W2883277239 hasConcept C55493867 @default.
• W2883277239 hasConcept C71924100 @default.
• W2883277239 hasConcept C86803240 @default.
• W2883277239 hasConcept C98274493 @default.

• next